History Podcasts

Results of the Alabama Primary February 4, 2008 - History

Results of the Alabama Primary February 4, 2008 - History


Alabama State Legislature

The Alabama State Legislature is the state legislature of Alabama. It is a bicameral body composed of the Alabama House of Representatives, with 105 members, and the Alabama State Senate, with 35 members. In the 2010 elections, Republicans gained control of both chambers for the first time since 1874.

The Legislature meets in the Alabama State House (officially designated as such by Amendment 427 to the Alabama Constitution) in Montgomery. The original capitol building located nearby has not been used by the Legislature since 1985, when it closed for renovations. It now serves as a museum.

Alabama has a Republican state government trifecta. A trifecta exists when one political party simultaneously holds the governor’s office and majorities in both state legislative chambers. As of June 22, 2021, there are 23 Republican trifectas, 15 Democratic trifectas, and 12 divided governments where neither party holds trifecta control.

In the 2020 election, Republicans had a net gain of two trifectas and two states under divided government became trifectas. Prior to that election, Alabama had a Republican trifecta. There were 21 Republican trifectas, 15 Democratic trifectas, and 14 divided governments.


In 2000 FDA issued a draft Guidance for Industry document, which provided recommendations for researchers submitting information to ClinicalTrials.gov. A final guidance document that incorporated comments from the public was issued in 2002 and was withdrawn by FDA in September 2017.

  • FDA Final Guidance, March 2002: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions (Withdrawn by FDA September 2017)

In January 2004 FDA proposed a revised draft Guidance for Industry document that included guidance for researchers submitting information required by the Best Pharmaceuticals for Children Act of 2002. This draft guidance was withdrawn by FDA in September 2017.

  • FDA Draft Guidance, January 2004: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions (Withdrawn by FDA September 2017)

We Grow Alabama

Natural Resources & Global Food Security and Hunger

91564 people

Community & Family Programs

$ 8.5 million
35982 people
17950 pounds
125721 young people
381385 people
ServSafe Class Chilton County
SERVSAFE FAYETTE AL FAYETTE COUNTY
STEM in the Garden: Teacher Training Workshop
Let's Have a DEEP Conversation about managing your diabetes.
Down & Dirty Home Garden Series

Find Extension programs near you.

4-H is for youth and 4-H is fun!

Find the latest news from Alabama Extension here.

Locate staff in counties, departments and program areas.

State Office

  • Duncan Hall
    Auburn University, AL 36849
  • Phone:(334) 844-4444
  • Hours: 7:45-11:45 12:45-4:45

Contact the State Office Locate nearest office

Find ACES on Flickr

Trade and brand names are given for information purposes only. No guarantee, endorsement, or discrimination among comparable products is intended or implied by the Alabama Cooperative Extension System.

For more information, contact your county Extension office. Visit www.aces.edu/directory.

The Alabama Cooperative Extension System (Alabama A&M University and Auburn University) is an equal opportunity educator and employer. Everyone is welcome! Please let us know if you have accessibility needs.

© 2021 by the Alabama Cooperative Extension System. All rights reserved.


We Grow Alabama

Natural Resources & Global Food Security and Hunger

91564 people

Community & Family Programs

$ 8.5 million
35982 people
17950 pounds
125721 young people
381385 people
ServSafe Class Chilton County
SERVSAFE FAYETTE AL FAYETTE COUNTY
STEM in the Garden: Teacher Training Workshop
Let's Have a DEEP Conversation about managing your diabetes.
Down & Dirty Home Garden Series

Find Extension programs near you.

4-H is for youth and 4-H is fun!

Find the latest news from Alabama Extension here.

Locate staff in counties, departments and program areas.

State Office

  • Duncan Hall
    Auburn University, AL 36849
  • Phone:(334) 844-4444
  • Hours: 7:45-11:45 12:45-4:45

Contact the State Office Locate nearest office

Find ACES on Flickr

Trade and brand names are given for information purposes only. No guarantee, endorsement, or discrimination among comparable products is intended or implied by the Alabama Cooperative Extension System.

For more information, contact your county Extension office. Visit www.aces.edu/directory.

The Alabama Cooperative Extension System (Alabama A&M University and Auburn University) is an equal opportunity educator and employer. Everyone is welcome! Please let us know if you have accessibility needs.

© 2021 by the Alabama Cooperative Extension System. All rights reserved.


1920s

January 1920: Dr. Alfred E. Thayer became acting dean of the medical school in Mobile. Dr. Thayer only served as acting dean through May.

June 1920: Dr. Daniel T. McCall, Sr., became acting dean of the Medical College of Alabama.

April 15, 1920: The University of Alabama Board of Trustees voted to “order the removal” of the medical school from Mobile to Tuscaloosa where the program would be reopened as a two-year preclinical school on the campus of the University.

May 28, 1920: Ten graduates received M.D. degrees from the Medical College of Alabama in the last commencement ceremony held in Mobile. Eleven other graduates received the Bachelor of Science in Medicine degree and two students received degrees in pharmacy.

1920: Medical College of Alabama was transferred from Mobile to The University of Alabama campus in Tuscaloosa where it was housed in a barracks building and reopened as a two-year basic sciences medical program.

1920: Dr. Clyde Brooks became the first dean of the University of Alabama’s two-year medical school in Tuscaloosa.

May 1921: The first two graduates received B.S. degrees in Medicine from The University of Alabama’s new two-year basic sciences medical program.

1922: Hillman Hospital received its first accreditation.

1922: Josiah Nott Hall was completed on the Tuscaloosa campus as a home to the two-year basic sciences medical program.

September 1923: Jimmie Ethel Montgomery entered the medical school in Tuscaloosa as the school's first full-time female student.

May 26, 1925: Jimmie Ethel Montgomery received a B.S. degree in Medicine from The University of Alabama, thus becoming the first female to graduate from the medical school.

1927: The University of Alabama Board of Trustees granted alumni status to all graduates of the Birmingham Medical College.

1928: Dr. Stuart Graves became the second dean of the University of Alabama’s two-year medical school in Tuscaloosa. He served until the school was moved to Birmingham in 1945.

January 15, 1929: The New Hillman Building was dedicated.

April 1929: Hillman Hospital School of Nursing Residence was dedicated.


The natural history of small-duct primary sclerosing cholangitis

Background & aims: The long-term prognosis of patients with small-duct primary sclerosing cholangitis (PSC) remains incompletely characterized. We aimed at determining the natural history and long-term outcomes of a large number of patients with small-duct PSC.

Methods: Data from 83 patients with well-characterized small-duct PSC from several medical institutions in Europe and the United States were combined. Each patient with small-duct PSC was randomly matched to 2 patients with large-duct PSC by age, gender, calendar year of diagnosis, and institution.

Results: The median age at diagnosis in both groups was 38 years (61% males). Nineteen (22.9%) of the 83 patients with small-duct PSC progressed to large-duct PSC in a median of 7.4 (interquartile range [IQR], 5.1-14) years. One patient with small-duct PSC who progressed to large-duct PSC was diagnosed with cholangiocarcinoma but after progression to large-duct PSC 20 patients with large-duct PSC developed cholangiocarcinoma. Patients with small-duct PSC had a significantly longer transplantation-free survival compared with large-duct PSC patients (13 years [IQR, 10-17] vs 10 years [IQR, 6-14], respectively hazard ratio, 3.04 95% confidence interval: 1.82-5.06 P < .0001). Two patients with small-duct PSC who underwent liver transplantation had recurrence of small-duct PSC in the graft 9 and 13 years, respectively, after transplantation.

Conclusions: Small-duct PSC is a disease of progressive potential but associated with a better long-term prognosis as compared with large-duct PSC. Small-duct PSC may recur after liver transplantation. Cholangiocarcinoma does not seem to occur in patients with small-duct PSC, unless the disease has progressed to large-duct PSC.


Patient Education

Patient education is key to successful long-term management. Migraine is a chronic neurologic disorder that requires a lifestyle change at some level.

For patient education information, see the Headache and Migraine Center, as well as the following:

References

Headache Classification Committee of the International Headache Society. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan. 38 (1):1-211. [Medline].

Hughes S. Choosing Wisely: 5 Headache Interventions Discouraged. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/814816. Accessed: November 25, 2013.

Loder E, Weizenbaum E, Frishberg B, Silberstein S the American Headache Society Choosing Wisely Task Force. Choosing Wisely in Headache Medicine: The American Headache Society's List of Five Things Physicians and Patients Should Question. Headache. Available at http://onlinelibrary.wiley.com/doi/10.1111/head.12233/abstract. Accessed: November 25, 2013.

[Guideline] Matchar DB, Young WB, Rosenberg JA, et al. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management of acute attacks. American Academy of Neurology. Accessed February 10, 2011. [Full Text].

Silberstein SD, Freitag FG. Preventative treatment of migraine. Neurology. 2003. 60(7):S38-44.

Anderson P. New Screening Tool for Chronic Migraine. Medscape Medical News. Available at http://www.medscape.com/viewarticle/831261. Accessed: September 8, 2014.

Anderson P. New Headache Classification System Published. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/807334. Accessed: July 15, 2013.

[Guideline] Solomon GD, Cady RK, Klapper JA, Ryan RE Jr. Standards of care for treating headache in primary care practice. National Headache Foundation. Cleve Clin J Med. 1997 Jul-Aug. 64(7):373-83. [Medline].

[Guideline] Ducharme J. Canadian Association of Emergency Physicians Guidelines for the acute management of migraine headache. J Emerg Med. 1999 Jan-Feb. 17(1):137-44. [Medline].

Perciaccante A. Migraine is characterized by a cardiac autonomic dysfunction. Headache. 2008 Jun. 48(6):973. [Medline].

May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab. 1999 Feb. 19(2):115-27. [Medline].

Cutrer FM, Charles A. The neurogenic basis of migraine. Headache. 2008 Oct. 48(9):1411-4. [Medline].

Waeber C, Moskowitz MA. Therapeutic implications of central and peripheral neurologic mechanisms in migraine. Neurology. 2003 Oct 28. 61(8 Suppl 4):S9-20. [Medline].

Welch KM. Contemporary concepts of migraine pathogenesis. Neurology. 2003 Oct 28. 61(8 Suppl 4):S2-8. [Medline].

Hauge AW, Asghar MS, Schytz HW, Christensen K, Olesen J. Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. Lancet Neurol. 2009 Aug. 8(8):718-23. [Medline].

Moulton EA, Burstein R, Tully S, Hargreaves R, Becerra L, Borsook D. Interictal dysfunction of a brainstem descending modulatory center in migraine patients. PLoS One. 2008. 3(11):e3799. [Medline]. [Full Text].

Richter F, Lehmenkühler A. [Cortical spreading depression (CSD): a neurophysiological correlate of migraine aura]. Schmerz. 2008 Oct. 22(5):544-6, 548-50. [Medline].

Martins-Oliveira A, Speciali JG, Dach F, Marcaccini AM, Gonçalves FM, Gerlach RF, et al. Different circulating metalloproteinases profiles in women with migraine with and without aura. Clin Chim Acta. 2009 Oct. 408(1-2):60-4. [Medline].

Imamura K, Takeshima T, Fusayasu E, Nakashima K. Increased plasma matrix metalloproteinase-9 levels in migraineurs. Headache. 2008 Jan. 48(1):135-9. [Medline].

Piilgaard H, Lauritzen M. Persistent increase in oxygen consumption and impaired neurovascular coupling after spreading depression in rat neocortex. J Cereb Blood Flow Metab. 2009 Sep. 29(9):1517-27. [Medline].

Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000 May. 47(5):614-24. [Medline].

Peroutka SJ. Dopamine and migraine. Neurology. 1997 Sep. 49(3):650-6. [Medline].

Sun-Edelstein C, Mauskop A. Role of magnesium in the pathogenesis and treatment of migraine. Expert Rev Neurother. 2009 Mar. 9(3):369-79. [Medline].

Napoli R, Guardasole V, Zarra E, Matarazzo M, D'Anna C, Saccà F, et al. Vascular smooth muscle cell dysfunction in patients with migraine. Neurology. 2009 Jun 16. 72(24):2111-4. [Medline].

Gruber HJ, Bernecker C, Lechner A, Weiss S, Wallner-Blazek M, Meinitzer A, et al. Increased nitric oxide stress is associated with migraine. Cephalalgia. 2010 Apr. 30(4):486-92. [Medline].

Tietjen GE, Herial NA, White L, Utley C, Kosmyna JM, Khuder SA. Migraine and biomarkers of endothelial activation in young women. Stroke. 2009 Sep. 40(9):2977-82. [Medline].

Hamed SA. The vascular risk associations with migraine: relation to migraine susceptibility and progression. Atherosclerosis. 2009 Jul. 205(1):15-22. [Medline].

Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008 Nov 25. 71(22):1821-8. [Medline].

Kors EE, Haan J, Ferrari MD. Genetics of primary headaches. Curr Opin Neurol. 1999 Jun. 12(3):249-54. [Medline].

Barbas NR, Schuyler EA. Heredity, genes, and headache. Semin Neurol. 2006 Nov. 26(5):507-14. [Medline].

Chasman DI, Schürks M, Anttila V, de Vries B, Schminke U, Launer LJ, et al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet. 2011 Jun 12. 43(7):695-8. [Medline]. [Full Text].

Anttila V, Stefansson H, Kallela M, Todt U, Terwindt GM, Calafato MS, et al. Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat Genet. 2010 Oct. 42(10):869-73. [Medline]. [Full Text].

Ligthart L, de Vries B, Smith AV, Ikram MA, Amin N, Hottenga JJ, et al. Meta-analysis of genome-wide association for migraine in six population-based European cohorts. Eur J Hum Genet. 2011 Aug. 19(8):901-7. [Medline]. [Full Text].

Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996 Nov 1. 87(3):543-52. [Medline].

Thomsen LL, Kirchmann M, Bjornsson A, Stefansson H, Jensen RM, Fasquel AC, et al. The genetic spectrum of a population-based sample of familial hemiplegic migraine. Brain. 2007 Feb. 130:346-56. [Medline].

Ferrari MD. Heritability of migraine. Neurology. 2003. 60(7):S15-20.

De Fusco M, Marconi R, Silvestri L, Atorino L, Rampoldi L, Morgante L, et al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genet. 2003 Feb. 33(2):192-6. [Medline].

Kahlig KM, Rhodes TH, Pusch M, Freilinger T, Pereira-Monteiro JM, Ferrari MD, et al. Divergent sodium channel defects in familial hemiplegic migraine. Proc Natl Acad Sci U S A. 2008 Jul 15. 105(28):9799-804. [Medline]. [Full Text].

Dichgans M, Freilinger T, Eckstein G, Babini E, Lorenz-Depiereux B, Biskup S, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet. 2005 Jul 30-Aug 5. 366(9483):371-7. [Medline].

Opherk C, Peters N, Herzog J, Luedtke R, Dichgans M. Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients. Brain. 2004 Nov. 127:2533-9. [Medline].

Richards A, van den Maagdenberg AM, Jen JC, Kavanagh D, Bertram P, Spitzer D, et al. C-terminal truncations in human 3'-5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet. 2007 Sep. 39(9):1068-70. [Medline].

Gould DB, Phalan FC, van Mil SE, Sundberg JP, Vahedi K, Massin P, et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med. 2006 Apr 6. 354(14):1489-96. [Medline].

Stam AH, Haan J, van den Maagdenberg AM, Ferrari MD, Terwindt GM. Migraine and genetic and acquired vasculopathies. Cephalalgia. 2009 Sep. 29(9):1006-17. [Medline].

MacGregor EA. Menstrual migraine. Curr Opin Neurol. 2008 Jun. 21(3):309-15. [Medline].

Allais G, Gabellari IC, De Lorenzo C, Mana O, Benedetto C. Oral contraceptives in migraine. Expert Rev Neurother. 2009 Mar. 9(3):381-93. [Medline].

Wöber C, Brannath W, Schmidt K, Kapitan M, Rudel E, Wessely P, et al. Prospective analysis of factors related to migraine attacks: the PAMINA study. Cephalalgia. 2007 Apr. 27(4):304-14. [Medline].

Klein E, Spencer D. Migraine frequency and risk of cardiovascular disease in women. Neurology. 2009 Aug 25. 73(8):e42-3. [Medline].

Woodward M. Migraine and the risk of coronary heart disease and ischemic stroke in women. Womens Health (Lond Engl). 2009 Jan. 5(1):69-77. [Medline].

Bushnell CD, Jamison M, James AH. Migraines during pregnancy linked to stroke and vascular diseases: US population based case-control study. BMJ. 2009 Mar 10. 338:b664. [Medline]. [Full Text].

Anderson, P. Migraine Tied to Hypertension Risk in Women. Medscape Medical News. Available at http://www.medscape.com/viewarticle/879249. April 28, 2017 Accessed: May 9, 2017.

Scher AI, Gudmundsson LS, Sigurdsson S, Ghambaryan A, Aspelund T, Eiriksdottir G, et al. Migraine headache in middle age and late-life brain infarcts. JAMA. 2009 Jun 24. 301(24):2563-70. [Medline].

Kurth T, Winter AC, Eliassen AH, Dushkes R, Mukamal KJ, Rimm EB, et al. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ. 2016 May 31. 353:i2610. [Medline].

Kruit MC, Launer LJ, Overbosch J, van Buchem MA, Ferrari MD. Iron accumulation in deep brain nuclei in migraine: a population-based magnetic resonance imaging study. Cephalalgia. 2009 Mar. 29(3):351-9. [Medline].

Welch KM. Iron in the migraine brain a resilient hypothesis. Cephalalgia. 2009 Mar. 29(3):283-5. [Medline].

Nguyen RH, Ford S, Calhoun AH, Holden JK, Gracely RH, Tommerdahl M. Neurosensory assessments of migraine. Brain Res. 2013 Jan 5. [Medline].

Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology. 2002 Mar 26. 58(6):885-94. [Medline].

Stewart WF, Linet MS, Celentano DD, Van Natta M, Ziegler D. Age- and sex-specific incidence rates of migraine with and without visual aura. Am J Epidemiol. 1991 Nov 15. 134(10):1111-20. [Medline].

Hsu LC, Wang SJ, Fuh JL. Prevalence and impact of migrainous vertigo in mid-life women: a community-based study. Cephalalgia. 2011 Jan. 31(1):77-83. [Medline].

Burton WN, Landy SH, Downs KE, Runken MC. The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. Mayo Clin Proc. 2009 May. 84(5):436-45. [Medline]. [Full Text].

Bille B. Migraine in childhood and its prognosis. Cephalalgia. 1981 Jun. 1(2):71-5. [Medline].

Milhaud D, Bogousslavsky J, van Melle G, Liot P. Ischemic stroke and active migraine. Neurology. 2001 Nov 27. 57(10):1805-11. [Medline].

Kruit MC, Launer LJ, Ferrari MD, van Buchem MA. Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain. 2005 Sep. 128:2068-77. [Medline].

Bigal ME, Kurth T, Hu H, Santanello N, Lipton RB. Migraine and cardiovascular disease: possible mechanisms of interaction. Neurology. 2009 May 26. 72(21):1864-71. [Medline]. [Full Text].

Scher AI, Terwindt GM, Picavet HS, Verschuren WM, Ferrari MD, Launer LJ. Cardiovascular risk factors and migraine: the GEM population-based study. Neurology. 2005 Feb 22. 64(4):614-20. [Medline].

Kurth T, Schürks M, Logroscino G, Buring JE. Migraine frequency and risk of cardiovascular disease in women. Neurology. 2009 Aug 25. 73(8):581-8. [Medline]. [Full Text].

Bigal ME, Kurth T, Santanello N, Buse D, Golden W, Robbins M, et al. Migraine and cardiovascular disease: a population-based study. Neurology. 2010 Feb 23. 74(8):628-35. [Medline].

Gudmundsson LS, Scher AI, Aspelund T, Eliasson JH, Johannsson M, Thorgeirsson G, et al. Migraine with aura and risk of cardiovascular and all cause mortality in men and women: prospective cohort study. BMJ. 2010 Aug 24. 341:c3966. [Medline]. [Full Text].

International Headache Society. IHS Classification ICHD-II: Migraine. Available at http://ihs-classification.org/en/02_klassifikation/02_teil1/01.00.00_migraine.html. Accessed: March 27, 2013.

Le H, Tfelt-Hansen P, Russell MB, Skytthe A, Kyvik KO, Olesen J. Co-morbidity of migraine with somatic disease in a large population-based study. Cephalalgia. 2011 Jan. 31(1):43-64. [Medline].

Martin VT, Fanning KM, Serrano D, Buse DC, Reed ML, Lipton RB. Asthma is a risk factor for new onset chronic migraine: Results from the American migraine prevalence and prevention study. Headache. 2015 Nov 19. [Medline].

Loder E. Migraine with aura and increased risk of ischaemic stroke. BMJ. 2009 Oct 27. 339:b4380. [Medline].

Kurth T, Kase CS, Schürks M, Tzourio C, Buring JE. Migraine and risk of haemorrhagic stroke in women: prospective cohort study. BMJ. 2010 Aug 24. 341:c3659. [Medline]. [Full Text].

Harling DW, Peatfield RC, Van Hille PT, Abbott RJ. Thunderclap headache: is it migraine?. Cephalalgia. 1989 Jun. 9(2):87-90. [Medline].

Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. Neurology. 1993 Sep. 43(9):1678-83. [Medline].

Anderson P. Neuropeptide May Be Biomarker for Chronic Migraine. Medscape Medical News. Aug 27 2013. [Full Text].

Cernuda-Morollón E, Larrosa D, Ramón C, et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013 Aug 23. [Medline].

Silberstein SD, Edvinsson L. Is CGRP a marker for chronic migraine?. Neurology. 2013 Aug 28. [Medline].

Wilper A, Woolhandler S, Himmelstein D, Nardin R. Impact of insurance status on migraine care in the United States: a population-based study. Neurology. 2010 Apr 13. 74(15):1178-83. [Medline].

Detsky ME, McDonald DR, Baerlocher MO, Tomlinson GA, McCrory DC, Booth CM. Does this patient with headache have a migraine or need neuroimaging?. JAMA. 2006 Sep 13. 296(10):1274-83. [Medline].

Sahai-Srivastava S, Desai P, Zheng L. Analysis of headache management in a busy emergency room in the United States. Headache. 2008 Jun. 48(6):931-8. [Medline].

Tornabene SV, Deutsch R, Davis DP, Chan TC, Vilke GM. Evaluating the use and timing of opioids for the treatment of migraine headaches in the emergency department. J Emerg Med. 2009 May. 36(4):333-7. [Medline].

Friedman BW, Solorzano C, Esses D, Xia S, Hochberg M, Dua N, et al. Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan. Ann Emerg Med. 2010 Jul. 56(1):7-17. [Medline]. [Full Text].

Kelman L. Women's issues of migraine in tertiary care. Headache. 2004 Jan. 44(1):2-7. [Medline].

US Food and Drug Administration. FDA allows marketing of first device to relieve migraine headache pain [press release]. December 13, 2013. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm378608.htm. Accessed: December 23, 2013.

Jeffrey S. FDA approves first device to treat migraine pain. Medscape Medical News. December 13, 2013. [Full Text].

Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010 Apr. 9(4):373-80. [Medline].

eNeura Therapeutics. Clinical trials -- study: migraine with aura. Available at http://www.eneura.com/clinical_trials.html. Accessed: January 28, 2014.

Holroyd KA, Cottrell CK, O'Donnell FJ, Cordingley GE, Drew JB, Carlson BW, et al. Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ. 2010 Sep 29. 341:c4871. [Medline]. [Full Text].

Brauser, D. FDA Clears Vagus Nerve Stimulator for Migraine Pain. Medscape Medical News. Available at https://www.medscape.com/viewarticle/891930. January 29, 2018 Accessed: January 30, 2018.

Yarnitsky D, Dodick DW, Grosberg BM, Burstein R, Ironi A, Harris D, et al. Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Headache. 2019 May 9. [Medline].

Derry S, Moore RA, McQuay HJ. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010 Nov 10. CD008040. [Medline].

Matchar DB. Acute management of migraine: highlights of the US Headache Consortium. Neurology. 60(7):S21-3.

Friedman BW, Mulvey L, Esses D, et al. Metoclopramide for acute migraine: a dose-finding randomized clinical trial. Ann Emerg Med. 2011 May. 57(5):475-482.e1. [Medline].

Taggart E, Doran S, Kokotillo A, Campbell S, Villa-Roel C, Rowe BH. Ketorolac in the treatment of acute migraine: a systematic review. Headache. 2013 Feb. 53(2):277-87. [Medline].

[Guideline] American Academy of Neurology. Practice parameter: appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1995 Mar. 45(3 Pt 1):585-7. [Medline].

Dowson AJ, Mathew NT, Pascual J. Review of clinical trials using early acute intervention with oral triptans for migraine management. Int J Clin Pract. 2006 Jun. 60(6):698-706. [Medline].

Barclay L. FDA Approves Transdermal Patch for Migraine. Available at http://www.medscape.com/viewarticle/777871. Accessed: January 29, 2013.

Cady RK, McAllister PJ, Spierings EL, Messina J, Carothers J, Djupesland PG, et al. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study). Headache. 2015 Jan. 55 (1):88-100. [Medline].

Anderson, P. FDA Okays Onzetra Xsail Intranasal Migraine Medication. Medscape Medical News. Available at http://www.medscape.com/viewarticle/857970. January 29, 2016 Accessed: February 3, 2016.

Brandes JL, Kudrow D, Stark SR, O'Carroll CP, Adelman JU, O'Donnell FJ, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007 Apr 4. 297(13):1443-54. [Medline].

Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB, et al. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018 Dec 11. 91 (24):e2222-e2232. [Medline]. [Full Text].

Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019 Jul 1. 142 (7):1894-1904. [Medline]. [Full Text].

Brandes JL, Klise S, Krege JH, Case M, Khanna R, Vasudeva R, et al. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia. 2019 Oct. 39 (11):1343-1357. [Medline]. [Full Text].

Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, et al. Ubrogepant for the Treatment of Migraine. N Engl J Med. 2019 Dec 5. 381 (23):2230-2241. [Medline].

Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, et al. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. JAMA. 2019 Nov 19. 322 (19):1887-1898. [Medline].

Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, et al. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019 Jul 11. 381 (2):142-149. [Medline]. [Full Text].

Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019 Aug 31. 394 (10200):737-745. [Medline].

Kostic MA, Gutierrez FJ, Rieg TS, Moore TS, Gendron RT. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. Ann Emerg Med. 2010 Jul. 56(1):1-6. [Medline].

Belotti EA, Taddeo I, Ragazzi M, Pifferini R, Simonetti GD, Bianchetti MG, et al. Chronic impact of topiramate on acid-base balance and potassium in childhood. Eur J Paediatr Neurol. 2010 Sep. 14(5):445-8. [Medline].

Misra UK, Kalita J, Bhoi SK. Allodynia in Migraine: Clinical Observation and Role of Prophylactic Therapy. Clin J Pain. 2013 Jan 16. [Medline].

[Guideline] Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr 24. 78(17):1346-53. [Medline]. [Full Text].

Krymchantowski AV, Jevoux C, Moreira PF. An open pilot study assessing the benefits of quetiapine for the prevention of migraine refractory to the combination of atenolol, nortriptyline, and flunarizine. Pain Med. 2010 Jan. 11(1):48-52. [Medline].

Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004 Feb 25. 291(8):965-73. [Medline].

Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, et al. Efficacy of gabapentin in migraine prophylaxis. Headache. 2001 Feb. 41(2):119-28. [Medline].

Jeffrey S. FDA Okays First Drug for Migraine Prevention in Adolescents. Medscape Medical News. Mar 28 2014. [Full Text].

Topamax (topiramate) prescribing information [package insert]. Titusville, NJ.: Janssen Pharmaceuticals, Inc., Titusville, NJ. March 2014. 2014. Available at [Full Text].

Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003 Jan 1. 289(1):65-9. [Medline].

Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ. 2001 Jan 6. 322(7277):19-22. [Medline]. [Full Text].

Conway S, Delplanche C, Crowder J, Rothrock J. Botox therapy for refractory chronic migraine. Headache. 2005 Apr. 45(4):355-7. [Medline].

Schulte-Mattler WJ, Martinez-Castrillo JC. Botulinum toxin therapy of migraine and tension-type headache: comparing different botulinum toxin preparations. Eur J Neurol. 2006 Feb. 13 Suppl 1:51-4. [Medline].

Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010 Jun. 50(6):921-36. [Medline].

[Guideline] Simpson David M., Hallett Mark, Ashman Eric J., et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. April 18, 2016. [Full Text].

Reuter U, Goadsby P, Lanteri-Minet M, Ferrari M, Wen S, Klatt J. Efficacy and safety of erenumab in episodic migraine patients with 2-4 prior preventive treatment failures: Results from the Phase 3b LIBERTY study. Presented at the American Academy of Neurology 2018 Annual Meeting. Emerging Science Abstract 009. April 24, 2018. Los Angeles, CA.

Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018 May. 38 (6):1026-1037. [Medline].

Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017 Nov 30. 377 (22):2123-2132. [Medline].

Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017 Nov 30. 377 (22):2113-2122. [Medline]. [Full Text].

Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol. 2018 Sep 1. 75 (9):1080-1088. [Medline]. [Full Text].

Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018 Jul. 38 (8):1442-1454. [Medline].

Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020 Feb 19. 333102420905132. [Medline].

Vyepti (eptinezumab) [package insert]. Bothell, WA: Lundbeck Seattle Biopharmaceuticals, Inc. February 2020. Available at [Full Text].

Jeffrey S. FDA Approves First Device to Prevent Migraine. Medscape Medical News. Available at http://www.medscape.com/viewarticle/821810. Accessed: March 17, 2014.

Walling I, Panse D, Gee L, Maietta T, Kaszuba B, Kumar V, et al. The use of focused ultrasound for the treatment of cutaneous allodynia associated with chronic migraine. Brain Res. 2018 Aug 2. [Medline].

Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache. 2001 Nov-Dec. 41(10):976-80. [Medline].

Alstadhaug KB, Odeh F, Salvesen R, Bekkelund SI. Prophylaxis of migraine with melatonin: a randomized controlled trial. Neurology. 2010 Oct 26. 75(17):1527-32. [Medline].

De Leo V, Scolaro V, Musacchio MC, Di Sabatino A, Morgante G, Cianci A. Combined oral contraceptives in women with menstrual migraine without aura. Fertil Steril. 2011 Oct. 96(4):917-20. [Medline].

von Peter S, Ting W, Scrivani S, Korkin E, Okvat H, Gross M, et al. Survey on the use of complementary and alternative medicine among patients with headache syndromes. Cephalalgia. 2002 Jun. 22(5):395-400. [Medline].

Lipton RB, Göbel H, Einhäupl KM, Wilks K, Mauskop A. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology. 2004 Dec 28. 63(12):2240-4. [Medline].

Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology. 1998 Feb. 50(2):466-70. [Medline].

Sándor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005 Feb 22. 64(4):713-5. [Medline].

Slater SK, Nelson TD, Kabbouche MA, LeCates SL, Horn P, Segers A, et al. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia. 2011 Jun. 31(8):897-905. [Medline].

Ferrari MD, Odink J, Tapparelli C, Van Kempen GM, Pennings EJ, Bruyn GW. Serotonin metabolism in migraine. Neurology. 1989 Sep. 39(9):1239-42. [Medline].

Arnadottir TS, Sigurdardottir AK. Is craniosacral therapy effective for migraine? Tested with HIT-6 Questionnaire. Complement Ther Clin Pract. 2013 Feb. 19(1):11-4. [Medline].

John PJ, Sharma N, Sharma CM, Kankane A. Effectiveness of yoga therapy in the treatment of migraine without aura: a randomized controlled trial. Headache. 2007 May. 47(5):654-61. [Medline].

Linde K, Vickers A, Hondras M, ter Riet G, Thormählen J, Berman B, et al. Systematic reviews of complementary therapies - an annotated bibliography. Part 1: acupuncture. BMC Complement Altern Med. 2001. 1:3. [Medline]. [Full Text].

Walker JE. QEEG-guided neurofeedback for recurrent migraine headaches. Clin EEG Neurosci. 2011 Jan. 42(1):59-61. [Medline].

Nestoriuc Y, Martin A. Efficacy of biofeedback for migraine: a meta-analysis. Pain. 2007 Mar. 128(1-2):111-27. [Medline].

Rosenzweig S, Greeson JM, Reibel DK, Green JS, Jasser SA, Beasley D. Mindfulness-based stress reduction for chronic pain conditions: variation in treatment outcomes and role of home meditation practice. J Psychosom Res. 2010 Jan. 68(1):29-36. [Medline].

Dirnberger F, Becker K. Surgical treatment of migraine headaches by corrugator muscle resection. Plast Reconstr Surg. 2004 Sep 1. 114(3):652-7 discussion 658-9. [Medline].

Rockett FC, de Oliveira VR, Castro K, Chaves ML, Perla Ada S, Perry ID. Dietary aspects of migraine trigger factors. Nutr Rev. 2012 Jun. 70(6):337-56. [Medline].

Tepper SJ. Complementary and alternative treatments for childhood headaches. Curr Pain Headache Rep. 2008 Oct. 12(5):379-83. [Medline].

Varkey E, Cider A, Carlsson J, Linde M. Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia. 2011 Oct. 31(14):1428-38. [Medline]. [Full Text].

Busch V, Gaul C. Exercise in migraine therapy--is there any evidence for efficacy? A critical review. Headache. 2008 Jun. 48(6):890-9. [Medline].

Durham PL, Garrett FG. Neurological mechanisms of migraine: potential of the gap-junction modulator tonabersat in prevention of migraine. Cephalalgia. 2009 Nov. 29 Suppl 2:1-6. [Medline].

Farinelli I, De Filippis S, Coloprisco G, Missori S, Martelletti P. Future drugs for migraine. Intern Emerg Med. 2009 Oct. 4(5):367-73. [Medline].

Dagenais R, Zed PJ. Intranasal lidocaine for acute management of primary headaches: a systematic review. Pharmacotherapy. 2018 Aug 11. [Medline].

[Guideline] Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr 24. 78 (17):1337-45. [Medline].

[Guideline] Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr 24. 78 (17):1346-53. [Medline].

Orr SL, Friedman BW, Christie S, Minen MT, Bamford C, Kelley NE, et al. Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies. Headache. 2016 Jun. 56 (6):911-40. [Medline].

[Guideline] Silberstein S. The Management of Adults With Acute Migraine in the Emergency Department. Headache. 2016 Jun. 56 (6):907-8. [Medline].

American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019 Jan. 59 (1):1-18. [Medline].

Brauser D. AHS Releases Updated Guidance on Migraine Treatment. Medscape Medical News. Available at https://www.medscape.com/viewarticle/907493. 2019 Jan 10 Accessed: January 31, 2019.

[Guideline] The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004. 24 Suppl 1:9-160. [Medline].

Imitrex (sumatriptan succinate) injection. Prescribing Information. GlaxoSmithKline. February 2010. [Full Text].

Imitrex (sumatriptan succinate) tablets. Prescribing Information. GlaxoSmithKline. February 2010. [Full Text].

Imitrex (sumatriptan) Nasal Spray. Prescribing Information. GlaxoSmithKline. February 2010. [Full Text].

Leonardi M, Mathers C. Global burden of migraine in the Year 2000: summary of methods and data sources. World Health Organization. Available at http://www.who.int/healthinfo/statistics/bod_migraine.pdf. Accessed: March 27, 2013.

Lowry F. Chronic Migraine Responds to OnabotulinumtoxinA. Medscape Medical News. Available at http://www.medscape.com/viewarticle/825002. Accessed: May 19, 2014.

Minson CT, Green DJ. Measures of vascular reactivity: prognostic crystal ball or Pandora's box?. J Appl Physiol. 2008 Aug. 105(2):398-9. [Medline].

[Guideline] Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr 24. 78(17):1337-45. [Medline]. [Full Text].


Historical Events in February 2008

    A major tornado outbreak across the Southern United States leaves at least 58 dead, the most since the May 31, 1985 outbreak that killed 88. 58th Berlin International Film Festival: "Elite Squad" wins the Golden Bear Nebraska bans electric chair as sole execution method The 2008 Namdaemun fire severely damages Namdaemun, the first National Treasure of South Korea.

Grammy Awards

Feb 10 50th Grammy Awards: Amy Winehouse wins 5 awards including song "Rehab", Herbie Hancock wins Album of the Year

BAFTA Awards

Feb 10 61st British Film and Television Awards (BAFTAS): "Atonement" Best Film, Ethan and Joel Coen Best Director

    In East Timor, assassination attempts were made on Xanana Gusmao and Jose Ramos-Horta. Both failed. Australian Prime Minister Kevin Rudd makes an historic apology to Indigenous Australians, especially to the Stolen Generations who suffered forced child removal and assimilation [1] The LZR Racer Suit is unveiled in NYC line of competition swimsuits made by Speedo using high-tech fabric of woven elastane-nylon & polyurethane times went down dramatically rules changed 2010 Northern Illinois University shooting: a gunman opened fire in a lecture hall of the DeKalb County, Illinois university resulting in 24 casualties 6 fatalities (including gunman) and 18 injured. 39th NAACP Image Awards: "The Great Debaters" wins Outstanding Motion Picture Kosovo declares independence from Serbia

NBA All-Star Game

Feb 17 57th NBA All-Star Game, New Orleans Arena, New Orleans, LA: East beats West, 134-128 MVP: LeBron James, Cleveland Cavaliers, F

    50th Daytona 500: Ryan Newman wins shootout going into the final turn from Tony Stewart, and the Busch brothers, Kurt and Kyle

Event of Interest

Feb 18 Laureus World Sports Awards, Marinsky Theatre, St. Petersburg, Russia: Sportsman: Roger Federer Sportswoman: Justine Henin Team: South African Men's National Rugby Union team

    Toshiba announces its formal recall of its HD DVD video format, ending the format war between it and Sony's Blu-Ray Disc Serzh Sargsyan wins the Armenian Presidential Election B-2 Spirit of the USAF crashes at Guam. Crew survives but aircraft written off, the most expensive air crash in human history (aircraft alone cost $1.2Bn). B-2 had a perfect safety record before the crash not one B-2 ever crashed. 28th Golden Raspberry Awards: "I Know Who Killed Me" wins

Event of Interest

Feb 24 Fidel Castro retires as the President of Cuba due to ill health after nearly fifty years


History of the Tea Party Movement

By Beth Rowen

One of several Tea Party protests

Related Links

Since its inception in February 2009, the Tea Party movement?with the help of viral videos and social networking sites, such as Facebook and Twitter?found a large and loyal following that quickly gained traction and supporters. However, the movement's electoral success in 2010 did not carry over to the 2012 or 2014 elections. In fact, by the 2014 elections, the consensus among many Republicans was that the Tea Party was too radical and was costing the GOP votes and seats in Congress.

A Televised Birth of a Movement

CNBC's Rick Santelli is widely credited with launching the grassroots movement. While standing on the floor of the Chicago Mercantile Exchange on February 19, 2009, he unleashed what can only be called a rant against the Obama Administration's proposal to help homeowners facing foreclosure refinance their mortgages.

"Do we really want to subsidize the losers' mortgages?" he asked. "This is America! How many of you people want to pay for your neighbor's mortgage that has an extra bathroom and can't pay their bills?" He went on to suggest that he would organize a Chicago Tea Party in July, where capitalists would dump "some derivative securities into Lake Michigan." The video of his tirade became a YouTube hit, and the movement was born. Within weeks, Tea Party protests were sprouting up all over the country. The Tea Party name, a clear reference to the American colonists' dumping of tea into Boston Harbor to protest taxes imposed by King George, stands as an acronym as well: Taxed Enough Already.

Santelli, however, can't claim credit as the sole mastermind of the movement. Prior to his appearance in Chicago, Keli Carender, a Seattle at-home mother also known as Liberty Belle, had been using her blog to get the word out about the populist "Porkulus Protest" she was organizing against President Barack Obama's proposed $750 billion stimulus package. About 100 people showed up for her event in mid-February. Similar events inspired by both Santelli and Carender, followed in quick succession in Denver Mesa, Ariz. Tampa, Fla. and other cities. Tea Party organizers claim that the first nationwide Tea Party protest took place on February 27, 2009, with coordinated events occurring in more than 40 cities.

Small Protests Gather Steam

These protests were merely dress rehearsal for the Tea Party events planned for April 15, 2009: tax day. Few can agree on the number of events held throughout the country the number ranges from 200 to 750, with total attendance ranging from about 250,000 to more than a half-million. Some protests, such as the one in Atlanta, Georgia, attracted crowds of several thousand others drew just a handful. A protest outside the White House was broken up by police when a demonstrator threw a box of tea bags over the fence.

Protests against the stimulus package, the bank bailouts, and health-care legislation continued throughout 2009, with major events held on July 4 and September 12. During the summer, Tea Party protesters were criticized for their disruptive outbursts during meetings held by members of Congress in their home districts to discuss health-care reform.

Diverse Group with a Unified Message

Tea Partiers detest all things big: big government, big business, big national debt, big taxes. They express hostility toward the elite and outrage that the government has come to the aid of Wall Street while ignoring the plight of Main Street. Most Tea Partiers consider themselves citizen activists who are part of a grassroots movement that is organized from the bottom up?small groups united under a shared ideology. The movement claims no national leader or figurehead. Some say that Sarah Palin assumed the role as #1 Tea Partier when she delivered the keynote address at the first Tea Party Convention in February 2010 in Nashville. Some 600 people attended the full convention, and another 500 sat in on Palin's speech only.

"America is ready for another revolution," she said. In a barb pointed at President Barack Obama, she said the movement is "about the people, and it's bigger than any one king or queen of a tea party, and it's a lot bigger than any charismatic guy with a teleprompter."

Growing Pains

Some members of the movement accused Tea Party Nation, the group that organized the convention, of attempting to profit from the event: tickets cost $549 to attend, and Palin received a reported $100,000 speaker's fee (which Palin said "will go right back to the cause"). Several sponsors and speakers backed out of commitments in the days and weeks leading up to the event. Representatives Michele Bachmann (R-Minn.) and Marsha Blackburn (R-Tenn.) were among the speakers to cancel their appearances.

While the Tea Party movement claims to be a grassroots movement, FreedomWorks, a powerful conservative organization headed by former congressman Dick Armey, seems to play an important role behind the scenes and serves as a clearinghouse for information on protests. Call it the right's answer to MoveON.org.

Mixed Electoral Results

While Democrats are usually the target of Tea Partiers' ire, Republicans have not always been spared. In New York, many members of the movement endorsed third-party candidate Doug Hoffman in the 2009 special election for the House seat vacated by John McHugh, over the moderate Republican candidate, Dede Scozzafava, pro-choice and a backer of gay marriage. Their plan backfired: Scozzafava withdrew from the race, and Democrat Bill Owens went on to win the election, albeit narrowly.

The ranks of Tea Party members grew in Congress throughout 2010. The movement's first major victory of the year occurred in January in Massachusetts?perhaps the bluest of the blue states?when Republican Scott Brown defeated Democrat Martha Coakley in the Senate race to fill the seat vacated after the death of Sen. Ted Kennedy. Brown somewhat distanced himself from the Tea Party during the race, but as he positioned himself as an outsider who would vote to block a vote on health-care reform, the movement claimed him as one of their own. In July Rep. Michele Bachmann (R-Minn.) got the go-ahead from the House leadership to form a Tea Party Caucus. Twenty-eight Republicans joined the group. In November's midterm elections, voters elected Kentucky's Rand Paul and Florida's Marco Rubio to the Senate. Exit polls on election day indicated that four out of ten voters have a favorable opinion of the party.

Voters, however, rejected some high-profile Tea Party candidates. Delaware's Christine O'Donnell, a conservative?and controversial?social activist who upset highly regarded political veteran Rep. Mike Castle in the September primary, was defeated in the general election by Democrat Christopher Coons. Sharron Angle, another controversial Tea Partier, lost her bid to unseat Harry Reid, the Senate majority leader from Nevada.

Tea Party candidates fared poorly in the 2012 election. Only four of 16 Senate candidates favored by the party were elected, and Representatives Allen West (R-FL) and Joe Walsh (R-IL), who were elected in 2010, were defeated. Tea Party favorite Michele Bachmann narrowly beat Democrat Jim Graves. However, despite the dwindling number of members of Congress from the Tea Party, many observers credit the party and its supporters for pressuring Speaker John Boehner to refuse to back down on defunding Obamacare during the budget showdown in late September 2013 that resulted in a partial government shutdown. The Republicans' approval rating plummeted after the shutdown, and many began to think twice about backing the Tea Party.

Is the Party Over?

By the 2014 midterm elections, several prominent Republicans had grown wary of the Tea Party's divisive, ideological agenda. The Chamber of Commerce poured about $7 million into the campaigns of establishment candidates. In Mississippi, the National Republican Senatorial Committee campaigned against the Tea Party's Chris McDaniel, who was challenging Sen. Thad Cochran. The stratgey worked not a single Tea Party candidate made it past the primary elections.


Watch the video: South Carolina primary coverage from ABC News Live (January 2022).